

899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002

April 6, 2023

9:30 am

**OPEN SESSION AGENDA  
(IN-PERSON AND WEBEX)**

**Board of Pharmacy Mission Statement:**

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”



## Open Session Agenda

Quorum:

<b>Introduction:</b>		
<b>0406-O-01</b>	<b><u>Approval of the Open Session Meeting Minutes for:</u></b>  February 2, 2023 March 9, 2023	
<b><u>Consent Agenda</u></b>	<b>None</b>	
<b><u>Chairperson Report</u></b>	<b><u>Interprofessional Workgroup</u></b>	Dr. Tamara McCants
<b><u>Executive Director Report</u></b>	<ul style="list-style-type: none"> <li>▪ Statistical Report on Pharmacy professionals in the District of Columbia</li> <li>▪ Prescription Drug Monitoring Program Updates</li> <li>▪ DCRx (DC Center for Rational Prescribing)</li> <li>▪ Office of Government Relations (OGR) Updates</li> <li>▪ Pharmacist and Pharmacy Technician Renewals</li> <li>▪ Pharmacy Facility Renewals</li> <li>▪ Board of Pharmacy Vacancies</li> </ul>	Dr. Justin Ortique
<b><u>Senior Assistant General Counsel Report</u></b>		
<b>0406-O-02</b>	None	Ms. Carla Williams
<b><u>Regarding Subcommittee Reports</u></b>		
<b>0406-O-03</b>	<b><u>Legislative and Regulatory Subcommittee Report</u></b>	Mr. Alan Friedman
<b>0406-O-04</b>	<b><u>Communications Subcommittee Report</u></b>	Dr. Ashlee Bow
<b><u>Matter for Consideration</u></b>		
<b>0406-O-05</b>	<b><u>Inquiry Regarding DC's CPA Law</u></b>  "Under section 10001.7(a)1C a pharmacist can certify as a specialist via "another credentialing body approved by the Board of Pharmacy" and I wanted to know if the Board has a list of approved credentialing bodies? If not, does one need to be formally approved by the Board?"	

	(a) Examination Handbook as a reference	
0406-O-06	<p><b><u>Scope of Practice Inquiry</u></b></p> <p>“Under the provisions of my Pharmacist license am I able to perform the following tasks in a person's residence without an established pharmacist-physician agreement.</p> <p>Working with individuals to increase compliance by helping them:</p> <ul style="list-style-type: none"> <li>▪ Manage the timing of the dosing regimen already prescribed by the physician.</li> <li>▪ Consult on side effects and adverse reactions they may experience.</li> <li>▪ Alert them of interactions with other medications they may be taking (consult Physician when needed)</li> <li>▪ Advise on appropriate spacing with other medications while maintaining the dosing schedule as prescribed by their physician.</li> <li>▪ Pillbox Filling”</li> </ul>	
0406-O-07	<p><b><u>Public Health Emergency (PHE) Expiration Impact on the Public Readiness and Emergency Preparedness (PREP) Act</u></b></p> <p>(a) Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap</p>	
0406-O-08	<b><u>MTM Services Out of the Office</u></b>	
0406-O-09	<b><u>Prescription Drug Monitoring Program (PDMP) Fine for Pharmacists</u></b>	
0406-O-10	<b><u>Continuing Education Audit Percentage for Pharmacists and Pharmacy Technicians</u></b>	
0406-O-11	<p><b><u>Requirement for Reinstatement for Pharmacists (Section 6513.13 of the District of Columbia Municipal Regulations for Pharmacists</u></b></p> <p>This matter comes before the Board for the following considerations:</p> <ol style="list-style-type: none"> <li>1. Revision of Section 6513.13(b), as a pharmacist applying for reinstatement of licensure is required to satisfy a requirement that does not exist in the updated DCMR, effective January 6, 2023.</li> <li>2. Inclusion of a time specification on satisfying the requirement mentioned in Section 6513.13(b), based on length of licensure expiration, (for example: should the pharmacist who forgot to renew his/her license and must now reinstate the license because it is just beyond the late renewal period, be subjected to 6513.13(b) just as well as the pharmacist whose license is expired for four (4) years?).</li> </ol>	

Whereas Section 6513.13 of the District of Columbia Municipal Regulations for Pharmacists (Hereinafter, "DCMR"), effective August 27, 2021 states:

"Beginning with the licensure period ending February 28, 2023, to qualify for a license, an applicant for reinstatement of a license shall submit proof, pursuant to § 6513.14, of having completed approved continuing education credit in the year immediately preceding the date of the application as follows: Title 17 District of Columbia Municipal Regulations Effective August 27, 2021:

(a) Forty (40) contact hours of approved continuing education credit which shall include at least:

(1) Two (2) hours in medication/dispensing errors training;

(2) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression ("LGBTQ"), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(3) At least ten percent (10%) of the total required continuing education shall be in the subjects determined by the Director as public health priorities of the District every five (5) years or less frequently, as deemed appropriate by the Director, with notice of the subject matter published in the D.C. Register. The Board shall disseminate the identified subjects to its licensees when determined by the Director via electronic communication and through publication on its website; and

(b) One hundred sixty (160) hours within a sixty (60) day period of professional practice under the supervision of a pharmacist performing tasks listed in § 6502.2(a),"

Where Section 6502.2(a) of the DCMR (2021) states:

"The Board shall give credit for independent pre-licensure professional practice required by §§ 6502.1(b)(2) and (3) if it meets the following requirements:

(a) Seventy percent (70%) of the work was spent performing the following pharmacy tasks:

(1) Filling prescriptions;

(2) Compounding drugs;

(3) Evaluating prescriptions

(4) Handling controlled substances;

(5) Handling toxic drugs and substances;

(6) Substituting generic drugs for brand name drugs;

(7) Storing and packing drugs;

(8) Instructing patients;

(9) Maintaining prescription records; and

(10) Handling veterinarian products[.]”

Section 6513.13 of the updated DCMR, effective January 6, 2023, states:

“Beginning with the licensure period ending February 28, 2023, to qualify for a

license, an applicant for reinstatement of a license shall submit proof, pursuant to

§ 6513.14, of having completed approved continuing education credit in the year

immediately preceding the date of the application as follows:

(a) Forty (40) contact hours of approved continuing education credit which

shall include at least:

(1) Two (2) hours in medication/dispensing errors training;

(2) Two (2) hours of continuing education on cultural competency or specialized clinical training focusing on patients or clients who identify as lesbian, gay, bisexual, transgender, gender nonconforming, queer, or question their sexual orientation or gender identity and expression (“LGBTQ”), meeting the requirements of D.C. Official Code § 3-1205.10(b)(5); and

(3) At least ten percent (10%) of the total required continuing education

shall be in the subjects determined by the Director as public health priorities of the District every five (5) years or less frequently, as deemed appropriate by the Director, with notice of the subject matter published in the D.C. Register. The Board shall disseminate the identified subjects to its licensees when determined by the

	<p>Director via electronic communication and through publication on its website; and</p> <p>(b) One hundred sixty (160) hours within a sixty (60) day period of professional practice under the supervision of a pharmacist performing tasks listed in § 6502.2(a),” thereby referencing section 6502.2(a), which is not documented in the updated DCMR.</p>	
<p><b>NABP E-Newsletter</b></p>	<p><b><u>March 29, 2023</u></b></p> <p>FDA Revises Janssen’s COVID-19 Vaccine Fact Sheet for Vaccination Providers</p> <p>As States Begin to Legalize ‘Magic’ Mushroom Use, Boards of Pharmacy and Pharmacists Should Stay Alert and Informed</p> <p>FDA Publishes Guidance on Use of Electronic Systems in Clinical Investigations</p> <p>University Training Program Gives 94% of Pre-Licensure Medical Providers a Better Understanding of OUD Treatment</p> <p>Nearly 50% of Fatal Poisonings in Children Involve Opioids, According to Study</p> <p>FDA Adds Marketing Reporting Requirements to the ‘Purple Book: Database of Licensed Biological Products FAQ’ Page</p> <p><b><u>March 22, 2022</u></b></p> <p>FDA Publishes Notice of COVID-19-Related Guidance Documents Expiring After Termination of the PHE</p> <p>FDA Releases Final Guidance Containing Definitions Relevant to DSCSA</p> <p>Convenience and Flexibility Are Some of the Reasons Why Patients Prefer Receiving OUD Medications at a Pharmacy</p> <p>Ethnographic Study Reveals Majority of Fentanyl, Heroin, and Methamphetamine-Based Counterfeit Pills Are Sold at Tourist-Oriented Pharmacies in Mexico</p> <p>DEA Agents Discuss Mexican Cartel’s Move Into Counterfeit Medications</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link:  <a href="https://nabp.pharmacy/newsroom/news/">https://nabp.pharmacy/newsroom/news/</a>.</p>	<p>Dr. Tamara McCants</p>

<b><u>Comments from the Public</u></b>		
<b><u>Motion to Adjourn the Open Session</u></b>	"Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." ROLL CALL VOTE	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

**Open Session Meeting Adjourned at \_\_:\_\_ AM.**

**This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at [opengovoffice@dc.gov](mailto:opengovoffice@dc.gov).**